Thomas Cluzeau, Cécile Favreau, Maxence Bourgoin, Geoffroy Venton, Raphaelle Fanciullino, Melanie Boucher, Caroline Fileni, Sami Benachour, Michael Loschi, Berengere Dadone-Montaudie, Patrick Auberger, Arnaud Jacquel, Guillaume Robert. "Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study." Blood, 2025. doi:10.1182/blood-2025-5250